GR1005052B - Συνθεσεις περιεχουσες αγωνιστη υποδοχεων s1p - Google Patents
Συνθεσεις περιεχουσες αγωνιστη υποδοχεων s1pInfo
- Publication number
- GR1005052B GR1005052B GR20040100121A GR2004100121A GR1005052B GR 1005052 B GR1005052 B GR 1005052B GR 20040100121 A GR20040100121 A GR 20040100121A GR 2004100121 A GR2004100121 A GR 2004100121A GR 1005052 B GR1005052 B GR 1005052B
- Authority
- GR
- Greece
- Prior art keywords
- agonist
- respector
- compositions
- comparising
- solid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46121503P | 2003-04-08 | 2003-04-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GR20040100121A GR20040100121A (el) | 2004-12-17 |
| GR1005052B true GR1005052B (el) | 2005-11-30 |
Family
ID=32326722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20040100121A GR1005052B (el) | 2003-04-08 | 2004-04-06 | Συνθεσεις περιεχουσες αγωνιστη υποδοχεων s1p |
Country Status (41)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007001236A (es) * | 2004-07-30 | 2007-03-23 | Novartis Ag | Formulaciones de compuestos de 2-amino-1, 3-propanodiol. |
| CN1891212B (zh) * | 2005-07-07 | 2010-10-13 | 马启明 | 一种口服制剂及其制备方法 |
| AU2006289100B2 (en) * | 2005-09-09 | 2010-07-22 | Novartis Ag | Treatment of autoimmune diseases |
| BRPI0618468A2 (pt) | 2005-11-09 | 2011-08-30 | Proteolix Inc | compostos para inibição de enzima |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| ES2415632T3 (es) | 2006-06-19 | 2013-07-26 | Onyx Therapeutics, Inc. | Epoxicetonas peptídicas para la inhibición del proteosoma |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| EP1923058A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Coated pharmaceutical composition comprising an S1P agonist or modulator |
| EP1923055A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator |
| EP1923054A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator |
| EP1905434A1 (en) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organic compounds comprising an S1P receptor agonist and their therapeutic use |
| BRPI0717570B8 (pt) | 2006-09-26 | 2021-05-25 | Novartis Ag | composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção |
| AU2011235934A1 (en) * | 2006-09-26 | 2011-11-03 | Novartis Ag | Pharmaceutical compositions comprising an S1P modulator |
| WO2008124210A1 (en) * | 2007-02-14 | 2008-10-16 | Emory University | Methods and compositions for treating or preventing infection using leukocyte sequestration agents |
| CA2680039C (en) * | 2007-03-29 | 2015-05-26 | Daiichi Sankyo Company, Limited | Pharmaceutical composition comprising edoxaban, an anticoagulant |
| ES2684340T3 (es) | 2007-10-04 | 2018-10-02 | Onyx Therapeutics, Inc. | Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos |
| AU2012216630B2 (en) * | 2007-10-12 | 2015-01-22 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators |
| MX337152B (es) * | 2007-10-12 | 2016-02-15 | Novartis Ag | Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p). |
| JP5534645B2 (ja) * | 2008-01-11 | 2014-07-02 | 日医工株式会社 | 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤 |
| US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
| LT2278960T (lt) | 2008-03-17 | 2017-02-10 | Actelion Pharmaceuticals Ltd. | S1p1 receptoriaus selektyvaus agonisto dozavimo režimas |
| WO2009152922A1 (de) * | 2008-06-20 | 2009-12-23 | Merck Patent Gmbh | Direkt verpressbare und schnell zerfallende tablettenmatirx |
| EP2303250A1 (en) | 2008-06-20 | 2011-04-06 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
| BRPI0919183B8 (pt) * | 2008-09-04 | 2021-05-25 | Cargill Inc | composição comprimível de eritritol, processo e uso do mesmo |
| MX2011004225A (es) | 2008-10-21 | 2011-06-21 | Onyx Therapeutics Inc | Terapia de combinacion con epoxicetonas peptidicas. |
| KR101393994B1 (ko) * | 2008-11-11 | 2014-05-14 | 노파르티스 아게 | 핑골리모드 ｈｃｌ의 결정질 형태 |
| AU2013100531B4 (en) * | 2008-11-11 | 2013-11-28 | Novartis Ag | Crystalline forms of fingolimod HCL |
| JP2012508215A (ja) | 2008-11-11 | 2012-04-05 | ノバルティス アーゲー | 有機化合物 |
| KR101463653B1 (ko) | 2008-12-17 | 2014-11-19 | 다이이찌 산쿄 가부시키가이샤 | 디아민 유도체의 제조 방법 |
| EP2383272A4 (en) | 2009-01-13 | 2012-07-25 | Daiichi Sankyo Co Ltd | ACTIVE BLOOD CREATION FACTOR HEMMER |
| CN102348688B (zh) | 2009-03-10 | 2014-07-09 | 第一三共株式会社 | 用于制备二胺衍生物的方法 |
| EP2407450B1 (en) | 2009-03-13 | 2015-04-22 | Daiichi Sankyo Company, Limited | Method for producing optically active diamine derivative |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| ES2605034T3 (es) * | 2009-06-18 | 2017-03-10 | Daiichi Sankyo Company, Limited | Composición farmacéutica con solubilidad mejorada |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| EP2498793B1 (en) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
| CN102892417A (zh) | 2010-03-01 | 2013-01-23 | 欧尼斯治疗公司 | 用于免疫蛋白酶体抑制的化合物 |
| KR101708528B1 (ko) | 2010-03-19 | 2017-02-20 | 다이이찌 산쿄 가부시키가이샤 | 디아민 유도체의 결정 및 그 제조 방법 |
| ES2601884T3 (es) | 2010-03-19 | 2017-02-16 | Daiichi Sankyo Company, Limited | Procedimiento para mejorar la capacidad de disolución de un anticoagulante |
| US20130095177A1 (en) * | 2010-04-22 | 2013-04-18 | Ratiopharm Gmbh | Method of preparing an oral dosage form comprising fingolimod |
| HUE031961T2 (en) | 2010-07-02 | 2017-09-28 | Daiichi Sankyo Co Ltd | A method for preparing an optically active salt of diamine derivative |
| US9266816B2 (en) | 2010-11-25 | 2016-02-23 | Shilpa Medicare Limited | Fingolimod polymorphs and their processes |
| KR102166885B1 (ko) | 2011-01-07 | 2020-10-19 | 노파르티스 아게 | 면역억제제 제제 |
| HUE038543T2 (hu) | 2011-01-19 | 2018-10-29 | Pathologica Llc | MGBG-t tartalmazó szabályozott kibocsátású orális gyógyszerészeti dózis-formák |
| JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
| WO2013019872A1 (en) | 2011-08-01 | 2013-02-07 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutical compositions comprising fingolimod |
| WO2013022059A1 (ja) | 2011-08-10 | 2013-02-14 | 第一三共株式会社 | ジアミン誘導体含有医薬組成物 |
| WO2013091704A1 (en) | 2011-12-22 | 2013-06-27 | Synthon Bv | Pharmaceutical composition comprising fingolimod |
| RU2482842C1 (ru) * | 2012-04-26 | 2013-05-27 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения |
| RU2506949C1 (ru) * | 2012-06-13 | 2014-02-20 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| RU2496486C1 (ru) * | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
| EP3831372A1 (en) | 2013-01-08 | 2021-06-09 | Pathologica LLC | Mitoguazone for preventing the relapse or the progression of multiple sclerosis |
| WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
| JP6294872B2 (ja) * | 2013-04-26 | 2018-03-14 | 国立大学法人京都大学 | 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物 |
| WO2013190151A1 (en) * | 2013-05-13 | 2013-12-27 | Synthon B.V. | Pharmaceutical composition comprising fingolimod |
| EP3027174B1 (en) | 2013-07-29 | 2019-07-24 | Aizant Drug Research Solutions Private Limited | Pharmaceutical compositions of fingolimod |
| RU2530626C1 (ru) * | 2013-10-21 | 2014-10-10 | Ооо "Валента-Интеллект" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| CN106794159A (zh) * | 2014-08-22 | 2017-05-31 | 广东东阳光药业有限公司 | 一种芬戈莫德固体组合物及其制备方法 |
| WO2016042493A1 (en) * | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| JP2018502168A (ja) * | 2015-01-20 | 2018-01-25 | ハンダ ファーマシューティカルズ エルエルシー | 安定な固体フィンゴリモド剤形 |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| RU2577230C1 (ru) * | 2015-04-09 | 2016-03-10 | Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" | Способ получения капсул финголимода гидрохлорида |
| US9690975B2 (en) | 2015-05-28 | 2017-06-27 | Axogen Corporation | Quantitative structural assay of a nerve graft |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| WO2018178744A1 (en) | 2017-03-29 | 2018-10-04 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
| GR1009654B (el) | 2018-08-31 | 2019-11-18 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| JP7503420B2 (ja) * | 2020-05-18 | 2024-06-20 | 東和薬品株式会社 | フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法 |
| EP4181906A1 (en) | 2020-07-16 | 2023-05-24 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection |
| AU2022214268A1 (en) * | 2021-01-28 | 2023-07-27 | Priothera Limited | Methods of treatment with s1p receptor modulators |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7607683A (nl) * | 1976-07-12 | 1978-01-16 | Akzo Nv | Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan. |
| US4110332A (en) * | 1977-05-05 | 1978-08-29 | Chevron Research Company | 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones |
| US4559153A (en) | 1983-10-25 | 1985-12-17 | Phillips Petroleum Company | Metal working lubricant |
| US5112616A (en) | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
| JP2841857B2 (ja) * | 1990-11-29 | 1998-12-24 | 田辺製薬株式会社 | 長期間安定な経口用医薬製剤 |
| EP0627406B1 (en) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| DK0778263T3 (da) | 1994-08-22 | 2002-04-22 | Mitsubishi Pharma Corp | Benzenforbindelser og farmaceutisk anvendelse af disse |
| AU705320B2 (en) | 1995-12-28 | 1999-05-20 | Welfide Corporation | 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| JP2002241272A (ja) * | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| GB9624038D0 (en) | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| EP0990440B1 (en) * | 1997-02-27 | 2008-10-29 | Novartis AG | Pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharide |
| SI1319651T1 (en) * | 1997-04-04 | 2005-10-31 | Mitsubishi Pharma Corporation | 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP3545595B2 (ja) | 1998-04-01 | 2004-07-21 | 花王株式会社 | スフィンゴ糖脂質の製造法 |
| JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| WO2001003739A1 (fr) * | 1999-07-12 | 2001-01-18 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate |
| CA2415678A1 (en) | 2000-07-13 | 2003-01-10 | Sankyo Company Limited | Amino alcohol derivatives |
| EP1315735A4 (en) | 2000-08-31 | 2005-04-06 | Merck & Co Inc | Phosphate derivatives as immunoregulatory compounds |
| US6953332B1 (en) | 2000-11-28 | 2005-10-11 | St. Jude Medical, Inc. | Mandrel for use in forming valved prostheses having polymer leaflets by dip coating |
| KR20030093279A (ko) | 2001-03-26 | 2003-12-06 | 노파르티스 아게 | 2-아미노-프로판올 유도체 |
| US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| JPWO2003020313A1 (ja) | 2001-09-04 | 2004-12-16 | 小野薬品工業株式会社 | スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤 |
| WO2003029184A1 (fr) | 2001-09-27 | 2003-04-10 | Kyorin Pharmaceutical Co., Ltd. | Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur |
| KR100913269B1 (ko) | 2001-09-27 | 2009-08-21 | 교린 세이야꾸 가부시키 가이샤 | 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제 |
| WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| DE60329073D1 (de) | 2002-01-18 | 2009-10-15 | Merck & Co Inc | Edg-rezeptoragonisten |
| JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Ｅｄｇ受容体に関連する症状の処置方法 |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| PT1772145E (pt) * | 2004-07-16 | 2011-05-27 | Kyorin Seiyaku Kk | Processo de utiliza??o eficaz de um medicamento e processo respeitante ? preven??o de efeitos secund?rios |
-
2004
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de not_active Ceased
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/en active Application Filing
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/en not_active Revoked
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en active Active
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Ceased
- 2004-04-06 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 CA CA2521325A patent/CA2521325C/en not_active Expired - Lifetime
- 2004-04-06 EP EP10186307A patent/EP2319502A1/en not_active Withdrawn
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 EP EP08161161A patent/EP2008650A3/en not_active Withdrawn
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko not_active Expired - Lifetime
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Ceased
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/en not_active Withdrawn
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 EP EP04725895A patent/EP1613288B1/en not_active Expired - Lifetime
- 2004-04-06 CA CA2707750A patent/CA2707750A1/en not_active Abandoned
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
-
2005
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
-
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
-
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
-
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
-
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-08 CY CY2011013C patent/CY2011013I1/el unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
-
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
-
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
-
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
-
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
-
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
-
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
-
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
-
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR20040100121A (el) | Συνθεσεις περιεχουσες αγωνιστη υποδοχεων s1p | |
| AU2003209475A1 (en) | Fast melt multiparticulate formulations for oral delivery | |
| BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
| MXPA03005257A (es) | Composiciones frarmaceuticas de un agonista del receptor de nmda. | |
| AU2003270255A1 (en) | Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve | |
| IL164440A0 (en) | New pharmaceutical composition containing fibanserin polymorph a | |
| AU2003246978A1 (en) | Pharmaceutical compositions comprising cyclosporin for oral administration | |
| NO20064808L (no) | Orale matrixformuleringer med licarbazepin | |
| DK1185253T3 (da) | Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac | |
| BRPI0413676A (pt) | composto, e, composição farmacêutica | |
| NO20013060D0 (no) | Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff | |
| IL179014A0 (en) | Film-shaped medicament for oral administration, containing estriol | |
| AU2003208395A1 (en) | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist | |
| GB2407498B (en) | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient | |
| AU2003245033A1 (en) | An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation | |
| TNSN06299A1 (en) | Oral matrix formulations comprising licarbazepine | |
| HK1071685B (en) | Pharmaceutical composition comprising an s1p receptor agonist | |
| WO2005037247A3 (en) | Oral matrix formulations of doxazosin | |
| MD20040296A (ro) | Compoziţie farmaceutică, conţinând oxcarbazepină cu eliberare prelungită a ingredientului activ |